Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Management of fever in neutropenic patients with different risks of complications Klastersky JClin Infect Dis 2004[Jul]; 39 Suppl 1 (ä): S32-7Risk stratification of febrile neutropenic patients can have important implications in terms of management. The first prospectively validated risk scoring system was developed in 1992. A subsequent scoring system was developed in 2000, in which a score of < or =21 predicts a <5% risk for severe complications. Oral combination therapy in an ambulatory or home care setting is acceptable for low-risk patients. Hospital admission is mandatory for high-risk patients. Intravenous monotherapy can be given if neutropenia is anticipated to be of short duration; it is also acceptable if neutropenia is expected to be more prolonged but the patients is stable and do not have an infectious focus. All other patients should receive combination therapy with an aminoglycoside, if infection with a gram-negative pathogen is suspected, or a glycopeptide, if a gram-positive organism is suspected. However, antimicrobial therapy with coverage against gram-negative organisms should always be provided because of the significant mortality associated with these infections.|*Immunocompromised Host[MESH]|Anti-Bacterial Agents/administration & dosage/*therapeutic use[MESH]|Bacteremia/*drug therapy[MESH]|Drug Therapy, Combination/*therapeutic use[MESH]|Fever/complications[MESH]|Gram-Negative Bacterial Infections/drug therapy[MESH]|Gram-Positive Bacterial Infections/drug therapy[MESH]|Humans[MESH]|Neutropenia/complications/*drug therapy[MESH]|Opportunistic Infections/*drug therapy[MESH]|Risk Assessment[MESH] |